Clinical Report: Breast Cancer Protocols Move Forward
Overview
The College of American Pathologists (CAP) has updated its breast cancer reporting protocols to align with the latest WHO classifications. Key revisions focus on tumor characterization, grading, and disease extent assessment.
Background
Accurate pathology reporting is crucial for effective breast cancer diagnosis and treatment planning. The updates to CAP's protocols reflect the latest WHO recommendations, ensuring that pathologists can provide consistent and high-quality reports.
Data Highlights
No numerical data provided in the source material.
Key Findings
- The CAP has updated eight cancer protocols, with significant changes to DCIS and invasive breast cancer protocols.
- Revisions include enhanced tumor characterization, grading, and disease extent assessment.
- New elements for reporting additional lesions have been introduced.
- Standardized reporting is intended to improve communication between pathologists and treating clinicians.
- Updates are part of CAP's quarterly protocol revisions and may have accreditation implications.
Clinical Implications
Pathologists should familiarize themselves with the updated protocols to ensure compliance with accreditation standards.
Conclusion
The updated breast cancer reporting protocols by CAP represent a significant step toward aligning clinical practice with the latest international standards.
Related Resources & Content
- College of American Pathologists, CAP Newsroom, 2026 -- CAP Updates Breast Cancer Reporting Protocols with Latest WHO Guidance
- Current Cancer Protocols - CAP, CAP, 2026 -- Current Cancer Protocols
- the asco post — CAP Issues New and Updated Cancer Protocols
- The ASCO Post — Highlights From the 2021 San Antonio Breast Cancer Symposium Guest Editors
- The ASCO Post — High-Risk, HER2-Positive Breast Cancer: Neoadjuvant and Adjuvant Treatment Options
- The ASCO Post — Breast Cancer Vaccines for Primary Prevention Move Toward Clinical Use
- CAP Issues New and Updated Cancer Protocols
- New WHO Classification for Breast Tumours online - ICCR
- Current Cancer Protocols - CAP
- CAP Updates Breast Cancer Reporting Protocols with Latest WHO Guidance
- HER2 Testing In Breast Cancer - 2023 Guideline Update - CAP
- HER2 Breast Cancer Testing Guideline Update FAQs
- FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer | FDA
- Leading Societies Update Clinical Guideline on Postmastectomy Radiation Therapy - The ASCO Post
- Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update - PubMed
- NCCN Guidelines Update Recommends Breast Cancer Screening at Age 35 for High-Risk Women Identified by AI | ASCO AI in Oncology
- NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
- Immunotherapy Combination: A Potential New Standard in Triple-Negative Breast Cancer - The ASCO Post
- Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population | Novartis
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
